Clinical Trials
22 trialsNCT02115295 2026-05-20
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03900949 2026-05-15
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00819546 2026-03-25
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT06313437 2026-03-25
Revumenib in Combination With 7+3 + Midostaurin in AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT04385290 2025-09-08
MOSAIC
Technische Universität Dresden
Phase 1/2 Recruiting
NCT03836209 2025-06-15
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
PrECOG, LLC.
Phase 2 Active not recruiting
NCT04027309 2024-12-17
HOVON 156 AML
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Active not recruiting
NCT04982354 2024-10-01
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT04496999 2022-10-06
HDMM
Insel Gruppe AG, University Hospital Bern
Phase 1 Terminated
NCT03951961 2022-01-21
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
University of Jena
Phase 2 Terminated
NCT00651261 2021-08-18
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT01830361 2020-08-06
MIDOKIT
Technische Universität Dresden
Phase 2 Completed
NCT01477606 2020-06-04
Protocol in Acute Myeloid Leukemia With FLT3-ITD
University of Ulm
Phase 2 Completed
NCT01282502 2018-12-12
Midostaurin (PKC412) for Locally Advanced Rectal Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT03207334 2018-10-22
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
University of Florida
Phase 2 Withdrawn
NCT01202877 2018-10-16
PKC412 and 5-Azacytidine
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01846624 2018-09-27
Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Stanford University
Phase 2 Terminated
NCT00233454 2018-09-20
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Stanford University
Phase 2 Completed
NCT01174888 2016-07-06
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01920204 2015-01-19
Midostaurin in Indolent Systemic Mastocytosis
University Medical Center Groningen
Phase 2 Unknown
NCT01161550 2013-07-23
CLAG ATRA AML
Washington University School of Medicine
Phase 1 Completed
NCT01130662 2013-03-26
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
University of Kansas Medical Center
Phase 1 Completed